Prognose

Vi har ingen analytikerdata for denne virksomhed.

Nyheder Til nyhedsfeedet

Tempus AI secures $1.1 billion in data contracts, shares rally

Tempus AI said it signed $1.1 billion in sealed data contracts with 70 customers in 2025, including major life-sciences firms such as AstraZeneca, Pfizer, Merck and Abbvie. The company reported revenue retention around 126% and called 2025 a record year for its Data and Applications business. Shares rose as much as 15% intraday and closed up 4.51% at $69.26. Tempus AI plans to finalize and report full 2025 financial results on an earnings call in February 2026. » Mere på finance.yahoo.com
Tempus AI raises FY25 guidance, cites FDA clearance and Paige acquisition as growth drivers

Tempus AI guided FY25 revenue to $1.25–$1.26 billion (about 81% YoY) and expects roughly $1.55 billion in FY26 revenue, valuing the company at ~9.16x 2026 sales. Recent catalysts include FDA clearance for its xR IVD product and the $81 million acquisition of Paige, which expand addressable markets and AI pathology capabilities. Analysts note strong revenue visibility and execution, while valuation appears supported by forward growth despite a trailing P/E around 41.5 and elevated share performance since April. » Mere på finance.yahoo.com
Tempus AI reaches all-time high of $98.14

Tempus AI stock climbed to an all-time high of $98.14, bringing market capitalization to about $16.16 billion. Analyst price targets range from $60 to $100; Guggenheim raised its target to $95 and H.C. Wainwright to $98. Tempus recorded revenue growth of 59.84% over the last twelve months and a 1-year performance of +96.54%. The company received FDA 510(k) clearance for the RNA-based diagnostic Tempus xR IVD and expanded its CARE program for breast cancer screening. » Mere på de.investing.com

Historisk udbytte Udbytte

Alle nøgletal for udbytte Alle nøgletal

I 2023 har TEMPUS CAPITAL INC. allerede udloddet 0,034 € i udbytte. Den seneste udlodning fandt sted i august 2023.

Virksomhedstal

I det seneste kvartal havde TEMPUS CAPITAL INC. en omsætning på 73,2 t € og et nettoresultat på -34,56 t €

(EUR)	juni 2026	YoY
Omsætning	73,2 t	2,72 %
Bruttofortjeneste	36,96 t	2,92 %
Nettoresultat	-34,56 t	11,85 %
EBITDA	2,21 t	243,99 %

Fundamentale data

Nøgletal	Værdi
Markedsværdi	1,14 mio. €
Antal aktier	30,48 mio.
Højeste/laveste i 52 uger	0,0528 € - 0,0249 €
Udbytte	Nej
Beta	-0,04
P/E (PE Ratio)	-7,14
PEG (PEG Ratio)	3,59
K/I (PB Ratio)	1,08
P/S (PS Ratio)	3,71

Virksomhedsprofil

Tempus Capital Inc. ist als Immobilienunternehmen in Kanada tätig. Das Immobilienportfolio des Unternehmens umfasst vier Immobilien, darunter eine Gewerbefläche, eine Gewerbeimmobilie und zwei gemischte Gewerbe-/Wohnimmobilien in Ontario. Tempus Capital Inc. wurde im Jahr 2011 gegründet und hat seinen Sitz in Burlington, Kanada.